EWMA 2020, 18-19 Nov

Larval debridement therapy: modern breakthroughs in an ancient solution

The session will take place 4th May 2017, 14.30-15.30.


Speakers and topics:

  • “The scientific modes of action of LDT” (40 min), Speaker TBA
  • “LDT case studies: bridging the theory-practice gap” (20 min), Speaker TBA


Learning objectives:


  • Delegates should understand that the evidence base for LDT is increasing.
  • Delegates should have an improved understanding of the microbiology underpinning the 3 reported clinical effects of LDT: debridement, anti-microbial activity, and improved wound healing outcomes.
  • Delegates should have an improved understanding of the active substances within LDT secretions which contribute to these 3 clinical effects, with particular focus on the activity of trypsin and chymotrypsin on the wound bed; the broad-spectrum anti-microbial activity of LDT, including evidence of prevention and removal of biofilms; and the remodelling action of LDT secretions in vitro, including cell migration and neovascularisation
  • Delegates should understand the level of evidence available for each of the actions of LDT
  • Delegates should be able to frame their understanding of the case studies presented within the context of the scientific evidence presented, with a new or increased understanding of the biochemical mechanisms that have given each clinical result.